Samantha Paoletti

We are happy to share with you a short video describing clearly and quickly what the SG-OCRA Technology is all about and how 1 minute of testing can help counter the often underestimated problem of Oral Cancer. OPEN VIDEO > https://lc.cx/rGqvfo #studiumgenetics #oralcarcinoma #oralcancer #headandneckcancer #oralcancerday

4

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy. We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

4

Pilatus Biosciences, a US/Swiss -based R&D startup originating from the Ludwig Institute for Cancer Research (Lausanne), stands on the cutting-edge of developing First-in-Class Biologics, focusing on metabolic checkpoints. Our pioneering approach, backed by the Cancer Research Institute (New York), targeting Immunometabolism triggers immune microenvironment reprogramming to combat cancer. Meet Pilatus Biosciences SA @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

2

1 Kommentar

📢𝗗𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝘁𝗵𝗲𝘀𝗲 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗶𝗻𝗴 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻𝘀 𝗯𝘆 𝗣𝗗 𝗗𝗿. Marc Pretze 𝗮𝘁 𝗘𝗔𝗡𝗠'𝟮𝟰! 👋 Join us at 𝗯𝗼𝗼𝘁𝗵 𝗛𝟭𝟵 during 𝗘𝗔𝗡𝗠'𝟮𝟰 in Hamburg for 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗤&𝗔 𝘀𝗲𝘀𝘀𝗶𝗼𝗻𝘀 by one of the 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝘃𝗼𝗶𝗰𝗲𝘀 𝗶𝗻 𝗮𝗹𝗽𝗵𝗮 𝗲𝗺𝗶𝘁𝘁𝗲𝗿 𝗿𝗮𝗱𝗶𝗼𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆, 𝗣𝗗 𝗗𝗿. 𝗠𝗮𝗿𝗰 𝗣𝗿𝗲𝘁𝘇𝗲! 🌟 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ▶️ 𝗔𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗦𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀: Discover the 𝗹𝗮𝘁𝗲𝘀𝘁 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 in automating the synthesis of radiopharmaceuticals labeled with alpha emitters. ▶️ 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗖𝗼𝗻𝘁𝗿𝗼𝗹: Learn about the 𝘀𝘁𝗮𝘁𝗲-𝗼𝗳-𝘁𝗵𝗲-𝗮𝗿𝘁 𝗺𝗲𝘁𝗵𝗼𝗱𝘀 in ensuring the 𝗵𝗶𝗴𝗵𝗲𝘀𝘁 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀 𝗼𝗳 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 for these innovative therapies. ▶️ 𝗢𝘃𝗲𝗿𝗰𝗼𝗺𝗶𝗻𝗴 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀: Dr. Pretze will dive into the 𝘂𝗻𝗶𝗾𝘂𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 associated with 𝗮𝗹𝗽𝗵𝗮 𝗲𝗺𝗶𝘁𝘁𝗲𝗿 𝗿𝗮𝗱𝗶𝗼𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 and how his team is 𝘁𝗮𝗰𝗸𝗹𝗶𝗻𝗴 𝘁𝗵𝗲𝘀𝗲 𝗶𝘀𝘀𝘂𝗲𝘀 at the Department of Nuclear Medicine, Universitätsklinikum Carl Gustav Carus Dresden and Technische Universität Dresden. 📅 𝗦𝗮𝘃𝗲 𝘁𝗵𝗲 𝗗𝗮𝘁𝗲! We're looking forward to seeing you all there. Join us in learning more about radiochemistry and 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝘆 𝘄𝗶𝘁𝗵 𝗮𝗹𝗽𝗵𝗮-𝗹𝗮𝗯𝗲𝗹𝗲𝗱 𝗰𝗼𝗺𝗽𝘂𝗻𝗱𝘀! 📄 Find out more in the 𝗳𝗹𝘆𝗲𝗿 𝗯𝗲𝗹𝗼𝘄 and join us for 𝗳𝗿𝘂𝗶𝘁𝗳𝘂𝗹 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻𝘀! #Radiochemistry #AlphaEmitters #Radiopharmaceuticals #NuclearMedicine #ContributingToSavingLives

86

1 Kommentar

Synendos Therapeutics AG is excited to announce the publication of the latest article written by Andrea Chicca and Jürg Gertsch, “CNS Drug Discovery in Academia: Where Basic Research Meets Innovation“, now available on #ChemBioChem: https://lnkd.in/eZ4mcQ7D In this article, they provide their perspective on the interaction between academia and drug discovery based on a 12-year experience with the NCCR-TransCure project, from which Synendos Therapeutics AG originated. Read the full article and discover how innovative research in academia can inspire drug discovery. #Biotech #Academia #drugdiscovery #ChemBioChem #SERI #endocannabinoidsystem

26

What’s more important in the search for novel cancer targets – sample quality or depth of multi-omic data analysis? At Indivumed we know: none works without the other but sample quality is the most critical part to achieve innovation. In a recent interview published in BIOCOM’s prestigious BioTechnologie Kursbuch, our founder Hartmut Juhl shared his thoughts on: 🔬 The progress we’ve made in using cutting-edge multi-omic analysis to explore our unique biobank of high-quality tissue samples. 🎯 The importance of precision in cancer treatment. We need the right target and the right patients for clinical trials. 🤖 Why artificial intelligence is a powerful analytical tool, integrated into target identification and validation alongside biomathematics, bioinformatics, and scientific expertise. 🧬 The paramount importance of tissue quality. Our recent data confirms that significant molecular changes occur just 12 minutes after removal from the patient. We are committed to leveraging unparalleled tissue quality and deep molecular data to identify novel targets that others cannot find. We're excited about the milestones ahead and our mission to bring hope to cancer patients worldwide by delivering on the promise of precision medicine. Read the original article in German here: https://lnkd.in/eTwiZN3S #CancerResearch #PrecisionMedicine #BioTechnologie #Oncology #Indivumed #CancerTreatment #biotech

16

Exciting new study alert! Professors Andrea B. Maier, @Carlos López-Otín, and Guido KROEMER, have published groundbreaking research in Nature Portfolio. They discovered that aging, like cancer, is driven by specific genes! In #cancer, mutations or overactive genes (#oncogenes) and failing tumor suppressor genes make cancer cells stronger and help them grow, dodging our body’s defenses. Similarly, #aging is influenced by genes that promote aging (#gerogenes) and the breakdown of protective genes. These genes impact overall health, leading to aging symptoms. By targeting these genes, precision medicine can be developed to slow aging and improve healthspan. This revolutionary approach offers hope for more personalized and effective treatments! Read more here: https://lnkd.in/eKN5eFz8 NUS Yong Loo Lin School of Medicine #CancerResearch #AgingScience #PrecisionMedicine #Genetics #HealthInnovation

51

1 Kommentar

Switzerland is one of the global leaders in life science. But who are the innovators that shape the future of #biotech? Check out what the startup community thinks. An update of the TOP 100 Public Voting: https://lnkd.in/dMwsPy6f TOP 3 in Biotech as of May 13: 1. Recolony AG: The startup focus is fighting cancer with a two-pronged approach. The first product is a unique, orally-delivered LBP targeting various solid tumors. This bacterial therapy works by stimulating specific immune cells through a well-defined mechanism, which Recolony has identified. https://lnkd.in/dv8bvkpB 2. HAYA Therapeutics: HAYA is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs. https://lnkd.in/dMbtRSP3 3. Navignostics AG: The startup characterizes tumors using spatial single-cell proteomics. It identifies a cancer treatment that will optimally fight each patient's tumor. https://lnkd.in/eH84t9q3 The race is still wide open, so keep spreading the word! Startups can share the link to the startup.ch voting page with friends, family, and followers and encourage everyone in the network to vote for them. Remember, every vote counts! How you can vote for your favorite TOP 100 Swiss startup: Voting is as easy as 1-2-3: 1. Visit https://lnkd.in/eNkbHTb9 for a list of all eligible startups. 2. Choose your winning startup and click the golden “Vote now” button on the startup’s profile. 3. Log in with your LinkedIn profile. Each user has one vote. Happy voting! All votes have to be in by July 21, 2024, at midnight. #TOP100SSU #SwissStartups #Switzerland

56

Great training, connections and resources from Masschallenge Switzerland. Happy to meet new friends from Azure Cell Therapies and Inkocell Therapeutics Thanks for the opportunity to share our vision in 30 seconds. Do you know how many lives we could save in just 30 seconds if we succeed? Every year, 2.3 million people die from ovarian, breast, and lung cancers, and current therapies aren't enough. RephImmune has developed a groundbreaking cell therapy called RACE to revolutionize cancer treatment. RACE has shown promising results for ovarian and breast cancer, bringing new hope to patients. Help us accelerate RACE into clinical practice, so we can save two lives every 30 seconds and change the future for millions. #masschallengeSwitzerland #OvarianCancer #Breastcancer #Lungcancer

15

Join us at the Future Labs Live Basel, where innovation meets expertise in the heart of Europe’s life sciences hub for two days! This event is a must-attend for professionals eager to stay ahead in the rapidly evolving laboratory technology field. Join us to the keynote: From Analog to Automated: A Step-by-Step Guide to the Future-Proof Laboratory 🗓️ June 26th, 2024, 1 pm CET 📍 Future Labs Live, Messe and Congress Center Basel In an era of technological leaps, it is crucial to understand how to transition from traditional analog methods to fully automated and digitalized systems. This keynote, led by industry experts - Philipp Osterwalder (CEO, 1LIMS), Simon Böhm (PM OMNIS Software, Metrohm AG), and Heike Risse (Head of Competence Center Liquid Handling & Lab Robotics, Metrohm IHQ) - offers a practical roadmap towards a seamless and efficient lab transformation. Why You Should Attend ➤ Expert Insights: Learn from leaders reshaping the lab operations landscape. Practical Steps: Gain a clear, step-by-step understanding of integrating new technologies into your lab operations. ➤ Future-proof strategies: Equip your laboratory for the challenges of tomorrow with strategies that enhance efficiency, accuracy, and reproducibility. ➤ Networking Opportunities: Connect with peers and industry leaders at the forefront of laboratory innovation. The transition from analog to automated doesn’t just promise enhanced lab efficiency; it is a strategic move to ensure your operations can meet future scientific demands with agility and precision. Whether you want to improve data integrity, reduce error rates, or streamline workflows, this session will provide the knowledge and tools necessary for a successful digital transformation. Don’t miss out on the chance to transform your laboratory’s future. Join us at Future Labs Live Basel 2024 for an enlightening journey from analog to automated. See you in #Basel! 👉 If you need a Ticket for the Future Labs Live 2024 in Basel, just send a DM. #FutureLabsLive2024

32

2 Kommentare

👩‍🔬 Meet Prof. Dr. Silvia Cappello and Rebecca Bonrath (PhD candidate) - our amazing team at The Ludwig Maximilian University of Munich!   The Capello Lab focuses on researching and characterizing cell lines of diverse neurodevelopmental disorders, including epilepsy, using different advanced techniques. Their expertise is crucial for the most critical steps of our project: validating the 3D-BrAIn platform and ensure its reliability and accuracy.   Specifically, the Capello lab has extensively studied cell lines with mutations in the FAT4 and DCHS1 genes, which provide a critical benchmark for testing the 3D-BrAIn platform. "We can compare the data from the 3D-BrAIn platform with the classical data we already have of these cell lines, to see if the 3D-BrAIn platform is working well," Rebecca explains.   Read more about the Silvia's and Rebecca's work and discover the potential of the 3D-BrAIn platform in our latest article: 👉 https://lnkd.in/dSSmwjhP

42

CHF 150,000 for next-gen cancer diagnosis: IMAI MedTech gets selected for final stage of Venture Kick. Congrats to the team of Francesca Catto, Robert Axelrod, and Sascha Brun. https://lnkd.in/eUXMKPma About: Cancer causes millions of deaths yearly. 2D histopathology, the main method for detecting cancer in tissue, involves the analysis of thin tissue slices. However, only a small percentage is examined, leading to false-negative results. The consequences are poor decisions, suboptimal treatments, and cancer recurrence. With its novel interdisciplinary approach combining biomedicine and mechanical engineering technologies, IMAI MedTech aims to enable doctors to adopt digital and 3D histopathology, enhancing accuracy, treatment outcomes, and ultimately improving survival rates. #VentureKick #SwissStartups

214

7 Kommentare

The "Deep Dive Journey Life Sciences" brought Swiss companies into the heart of Bavaria's thriving biotech and life sciences ecosystem. From exploring leading innovation hubs like BioM Biotech Cluster Development GmbH, the IZB - Innovation and Start-up Center Biotechnology in Martinsried, BioPark Regensburg GmbH, and the Medical Valley in Erlangen to engaging with pioneering companies such as Roche Diagnostics, FUJIFILM medwork GmbH, and Novartis, participants gained unparalleled insights into Bavaria's industry landscape.🔬 The first day set the tone for collaboration, starting with impactful opening remarks from Verena Stübner (Handelskammer D-CH), Eros Robbiani (Swiss General Consulate), and Dr. Lukas Julian Keller (Swiss Business Hub Germany). Highlights included presentations on groundbreaking therapies from Immunic Therapeutics and advanced cell culture solutions from PELOBiotech GmbH, along with site visits to the Biomedical Center Munich and Labvantage - Biomax GmbH.🌍 Networking opportunities were abundant, with a standout moment being the dinner officially opened by Tobias Gotthardt fostering valuable connections and discussions. This journey emphasized the shared strengths of Bavaria and Switzerland as global biotech leaders, showcasing their commitment to advancing innovation in areas such as orphan drugs, advanced diagnostics, and life sciences research. It served as a powerful reminder of the potential for cross-border collaborations to shape the future of healthcare. More about Health, MedTech and Life Sciences in Bavaria: https://lnkd.in/dcku9sZP Bayern Innovativ GmbH I Gesundheit bei Bayern Innovativ I Universitätsklinikum Regensburg I Medical Valley EMN e. V. #LifeSciences #Bavaria #Switzerland #Innovation #Biotech #Collaboration

105

1 Kommentar

⏰ 5 weeks to go! 🗓   🎊 Beyond PANCAIM, Tumor-LN-oC, eCAP Project and NetZeroAICT - check out our last post... We are excited to present more of the exciting #Health and #Biotech projects in our portfolio at the upcoming #COMPAMED Conference in Düsseldorf from 11-14 November 2024!   👩‍⚕️ Funded by European Health and Digital Executive Agency (HaDEA), these projects represent cutting-edge innovation in #healthcare and #medicaltechnology, aimed at transforming #clinical practice and #patient care across Europe in a broad range of areas!   🔹UltraSense EU: This brand new project - just launched in September 2024 - is developing an innovative stretchable multi-sensing platform aims to provide comprehensive body composition analysis and decentralised health monitoring.   🔹ECOTRON: The EU-funded project is developing adaptable organic and eco-friendly printed electronics solutions that allow for improved and expanded recycling while impacting the environment less during production.   🔹RES-Q+ project will capitalize on the Registry of Stroke Care Quality currently used by 80+ countries in the EU and beyond for collecting and analysing data on quality of stroke care.   👋 Come and visit our booth at #COMPAMED (Hall 8a, booth M29) to learn more about these innovative projects and how you could get engaged in #collaborative #research and #innovation projects with #EUfunding!   #COMPAMED2024 #MedicalInnovation #HealthcareTransformation #AIinHealthcare #PersonalizedMedicine #MedicalDevices

10

For all of you who can't wait or unfortunately can't attend the ACROConnect workshop at Novartis Campus in Basel, here is a little insight into one of our R&D projects on TCRm, presented by our VP Services & Operations Philipp Kuhn.   Classical antibodies in oncology bind to extracellular targets. The problem is that >80% of the proteome are intracellular proteins and therefore can't be reached by classical antibodies. However, the fact that intracellular proteins are presented as peptides on MHCI complexes and can therefore be recognized by TCRs is a game changer for tumor therapy, ushering in the era of TCRm. TCRm antibodies can precisely recognize this peptide-MHCI complex. The tricky part is to bind only the tumor-specific peptides and avoid off-target effects. Using our naïve human antibody library, we have developed TCRm antibodies that recognize the Wilms tumor antigen WT1 but not the negative control, and outperform reference antibodies in several aspects. This proof of concept was just a precursor for further TCRm antibodies from our workshop. Stay tuned! #YUMAB #Antibodies #TCRm #ACROBiosystems

27

🌐 English Version: Advanced Biobanking for Oncology 🌐 The BioBank Dresden (BBD) is pushing the boundaries of cancer research with state-of-the-art processes for the secure and efficient handling of biosamples. In collaboration with DKFZ and NCT Dresden, samples are processed and cryopreserved in LVL SAFE® 2D Tubes, ensuring they’re available for precise, long-term research needs. The full application note is available in the attachment. #BioBankDresden #CancerResearch #Biobanking #Oncology #Research

40